蛋白酶体是细胞调节信号的中心通道,可以降解和活化多种调节蛋白;蛋白酶体抑制剂可通过抑制催化中心活性,阻断大量调节蛋白的降解,引起细胞内信号系统的紊乱和超负荷,导致细胞生长的抑制,最终使肿瘤进展过程延缓甚至停滞。Bortezomib作为第一个选择性的蛋白酶体抑制剂在多发性骨髓瘤(MM)中有良好的治疗反应率和较少的毒副作用,近年来得到广泛研究。 Proteasomes are central pathways for cellular signaling and can degrade and activate a variety of regulatory proteins. Proteasome inhibitors can block and overload the regulatory signaling system by disrupting catalytic center activity and causing disruption and overload of intracellular signaling systems, Inhibition of cell growth, the final delay in the process of tumor progression or even stagnation. Bortezomib has been widely studied in recent years as the first selective proteasome inhibitor with good therapeutic response and less toxic side effects in multiple myeloma (MM).